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AUC0–∞ values were obtained, respectively, for patients with psoriasis 
and healthy volunteers: (S)-(+)-VLX, 729.7 vs 647.9 ng·h/mL; (R)-(-)-
VLX, 532.0 vs 327.6 ng·h/mL; (S)-(+)-ODV, 2742.7 vs 2463.1 ng·h/
mL; (R)-(-)-ODV, 2977.0 vs 2603.6 ng·h/mL; (S)-(+)-NDV, 281.7 vs 
60.8 ng·h/mL; (R)-(-)-NDV, 507.2 vs 192.3 ng·h/mL; (S)-(+)-DDV, 
758.6 vs 585.5 ng·h/mL; and (R)-(-)-DDV, 563.5 vs 482.9 ng·h/mL.
Conclusion: Psoriasis did not alter the kinetic disposition and metab-
olism of venlafaxine enantiomers following a single oral administra-
tion of the racemic drug.
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Introduction: Critically ill patients may display altered pharmacoki-
netic parameters. Therapeutic drug monitoring (TDM) is essential 
to optimize the use of antibiotics in intensive care units. Many TDM 
assessments may be inappropriate as a result of improper interpreta-
tion or collection timing. We assessed the practice of TDM of vanco-
mycin and aminoglycosides in an adult intensive care unit.
Patients (or Materials) and Methods: We performed a retrospective 
analysis of all vancomycin and aminoglycosides plasma level deter-
minations performed between January 1, 2011, and December 31, 
2011, in adult patients admitted in the intensive care unit of Geneva 
University Hospitals, Switzerland.
Results: A total of 845 antibiotic plasma levels were performed 
in 193 patients, among which 773 levels could be interpreted. The 
majority of TDM were related to vancomycin (87%), while amino-
glycoside TDM were less frequent (13%). For intermittent vanco-
mycin, the dosage was not changed in 27% of high through levels 
and 23% of low through levels. A dosage increase was observed in 
only 22% of low through levels. Moreover, about one half of the 
samples were drawn too early. For continuous vancomycin, dosage 
was not changed in 17% of high plasma levels and 33% of low levels. 
A dosage increase was observed in only 30% of low levels. About 
60% of the samples were drawn too early. For aminoglycosides, the 
dosage was not changed in 20 to 30% of the cases when high through 
levels were measured. As for vancomycin, samples were frequently 
drawn too early.
Conclusion: Our results show that the practice of TDM of vanco-
mycin and aminoglycosides could be improved. Too high or too low 
levels did not systematically result in dosage changes and samples 
were frequently drawn too early.
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Introduction: In critically ill patients with hospital-acquired pneu-
monia, pathophysiologic changes alter the pharmacokinetics of 
antibiotics. Imipenem exhibits primarily time-dependent killing. Its 
administration by prolonging the intermittent infusion may increase 
time with serum concentrations above the minimum inhibitory con-
centration of the suspected pathogens (t > MIC).
Patients (or Materials) and Methods: Inclusion criteria were hos-
pital-acquired pneumonia, treatment by imipenem/cilastatin, and 
expected continuation of mechanic ventilation for at least 48 hours 
from the recruitment into the trial. Enrolled patients were randomly 
divided into either bolus group (to receive 1-g imipenem over 30 
minutes every 8 hours) or extended group (0.5 g administered over 
3 hours every 6 hours). Imipenem plasma concentrations were deter-
mined by reversed-phase HPLC during the second day of imipenem 
treatment. Pharmacokinetic data were determined using a 1-compart-
ment model. The target pharmacokinetic/pharmacodynamic param-
eter, percentage of dosing interval in which plasma concentration of 
imipenem exceeded 4 times the minimum inhibitory concentration 
(%t > 4 × MIC), was assessed using individual concentration–time 
curves for MIC of 0.5, 1, and 2 mg/L. Kolmogorov-Smirnov test was 
used to confirm normal distribution of data, which were then tested 
by unpaired t test.
Results: Twenty-two patients entered this study. Patients in both 
groups were matched with regard to other demographic data, renal 
functions, and severity of illness. The parameter % t > 4 × MIC was 
comparable in both groups for MIC of 0.5 mg/L, ranging from 74% 
to 100% in bolus group and from 55% to 100% in extended group. 
For MIC of 1 mg/L, the difference in both groups was not statistically 
significant, ranging from 59% to 100% in bolus group and from 
31% to 100% in extended group. However, in the extended group, 
in 2 patients (20%) imipenem concentration in plasma did not remain 
above 4 × MIC for 40 % of the dosing interval. All patients in the 
bolus group achieved the PK/PD target for MIC of 2 mg/L. In the 
extended group, majority of the patients did not achieve this target. 
On the other hand, imipenem plasma concentration was above 4 × 
MIC of 2 mg/L for more than 90% of the dosing interval in 1 patient 
in extended group.
Conclusion: In artificially ventilated patients with hospital-acquired 
pneumonia, prolonged infusion of imipenem/cilastatin to 3 hours 
(with reduced total daily dose) does not lead to an improvement of 
the main tested PK/PD parameter - time upon the 4 times suspected 
pathogen’s MIC.
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Introduction: Darunavir (DRV), a protease inhibitor, potently sup-
presses the replication of wild-type and drug-resistant HIV-1, but 
its clinical efficacy varies greatly among individuals. Recently, the 
importance of the concentrations of DRV in blood cells, the site of 
action for DRV, has been focused. In this study, we assessed the influ-
ence of plasma and intracellular concentration of DRV on its clinical 
efficacy. The factors acting for the intracellular concentration of DRV 
is also investigated.
